TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20714991

Group type: EXPERIMENTAL
Intervention: Oral lutein supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed lutein/omega-3-fatty acid combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-wavelength reflection method
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-wavelength auto-fluorescence method
Number of subjects: 0
Study: 20073226

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) on the bilateral Zusanli (ST36) and Tianshu (ST25) points
Number of subjects: 66

Group type: COMPARATOR
Intervention: Citrate-mosapride tablet
Number of subjects: 66
Study: 16427930

Group type: EXPERIMENTAL
Intervention: Ileocolonoscopy by trainees
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ileocolonoscopy by seniors
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ileoscopy skill measurements
Number of subjects: 100
Study: 14723858

Group type: EXPERIMENTAL
Intervention: Palpation of the primary respiratory mechanism (PRM)
Number of subjects: 49
Study: 11691566

Group type: EXPERIMENTAL
Intervention: Cefaclor (25 mg/kg/bid) for 5 days
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cefaclor (25 mg/kg/bid) for 10 days
Number of subjects: 138
Study: 9143642

Group type: EXPERIMENTAL
Intervention: Yohimbine 20 mg once a day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Yohimbine 5 mg three times a day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Yohimbine 10 mg three times a day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31187203

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LHRH agonist monotherapy
Number of subjects: 80
Study: 29926560

Group type: EXPERIMENTAL
Intervention: Advanced nurse triage during overcrowding periods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional triage
Number of subjects: 0
Study: 26592857

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 24684171

Group type: EXPERIMENTAL
Intervention: Pulse-train stimulation within the pedicle track using a ball-tipped probe and electromyography from lower limb muscles
Number of subjects: 71

Group type: COMPARATOR
Intervention: Direct screw stimulation and electromyogram response from intercostal, abdominal, or lower limb muscles
Number of subjects: 71
Study: 23460709

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy (arm A)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m(2) on days 1, 22, and 43 combined with 70 Gy of radiotherapy and erlotinib 150 mg per day (arm B)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Cisplatin and radiotherapy (arm A)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cisplatin and radiotherapy with erlotinib (arm B)
Number of subjects: 204
Study: 19698856

Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 17643
Study: 17979577

Group type: EXPERIMENTAL
Intervention: Moderate to severe ADHD treatment
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Co-morbid communication disorders
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 303
Study: 15494637

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy concurrently with weekly gemcitabine at 300 mg/m2
Number of subjects: 9
Study: 11710635

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 i.v. bolus) followed 24 h later by paclitaxel (200 mg/m2 i.v. over 3 h)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 i.v. bolus) followed 30 min later by paclitaxel (200 mg/m2 i.v. over 3 h)
Number of subjects: 28
Study: 9741730

Group type: EXPERIMENTAL
Intervention: CPAP group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oxygen group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intubation group
Number of subjects: 29
Study: 8045206

Group type: EXPERIMENTAL
Intervention: First group intestinal preparation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Second group intestinal preparation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Third group intestinal preparation
Number of subjects: 6
Study: 3198299

Group type: EXPERIMENTAL
Intervention: Erythromycin propionate-N-acetylcysteinate (EPAC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Erythromycin stearate (ES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC)
Number of subjects: 12
Study: 1119589

Group type: EXPERIMENTAL
Intervention: Short-term hospitalization
Number of subjects: 141

Group type: COMPARATOR
Intervention: Long-term hospitalization
Number of subjects: 141
Study: 31436475

Group type: EXPERIMENTAL
Intervention: G2 - two bleaching sessions with violet LED light (405-410 nm), 30 min each session
Number of subjects: 50

Group type: COMPARATOR
Intervention: G1 - two bleaching sessions with 35% carbamide peroxide, 30 min each session
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 30682044

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 27317414

Group type: EXPERIMENTAL
Intervention: Idarucizumab (1, 2.5 and 5 g or 2 × 2.5 g 1 h apart)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Idarucizumab (doses ≥2.5 g)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 26637922

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 115

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 115
Study: 24431895

Group type: EXPERIMENTAL
Intervention: LdT (600 mg/d orally) + ADV (10 mg/d orally)
Number of subjects: 106

Group type: COMPARATOR
Intervention: LAM (100 mg/d orally) + ADV (10 mg/d orally)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: LdT + ADV
Number of subjects: 106

Group type: COMPARATOR
Intervention: LAM + ADV
Number of subjects: 106
Study: 21370724

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 24
Study: 18450930

Group type: EXPERIMENTAL
Intervention: Treatment for late-life depression (structured conditions for up to 12 weeks)
Number of subjects: 461
Study: 17905084

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL
Number of subjects: 126

Group type: COMPARATOR
Intervention: Regular PCNL
Number of subjects: 126
Study: 14679117

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 (arm A)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 (arm B)
Number of subjects: 182
Study: 11136915

Group type: COMPARATOR
Intervention: Acute phase of stroke
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Convalescent period
Number of subjects: 106
Study: 9134632

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for up to six months (discontinued after the first event)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Patients with factor V Leiden
Number of subjects: 380

Group type: COMPARATOR
Intervention: Patients without factor V Leiden
Number of subjects: 380
Study: 7696826

Group type: EXPERIMENTAL
Intervention: Sangemini mineral water
Number of subjects: 18

Group type: COMPARATOR
Intervention: Milk calcium
Number of subjects: 18
Study: 3585679

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine chewing gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chewing gum without nicotine (placebo)
Number of subjects: 20
Study: 31268011

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Infusion therapy
Number of subjects: 84
Study: 27986370

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (no ethyl chloride spray)
Number of subjects: 275
Study: 24739800

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 23881346

Group type: EXPERIMENTAL
Intervention: BIB® (6 months) followed by diet therapy (7 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Consecutive BIB® placement for 6 months followed by another BIB® for 6 months (with a 1-month interval)
Number of subjects: 50
Study: 21976264

Group type: EXPERIMENTAL
Intervention: Client-oriented Occupational Therapy methods
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 19908309

Group type: EXPERIMENTAL
Intervention: DBS ON
Number of subjects: 14

Group type: COMPARATOR
Intervention: DBS OFF
Number of subjects: 14
Study: 16924183

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation exercise program
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 15481405

Group type: EXPERIMENTAL
Intervention: On-site shielding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous broadband RF recording
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple sleep monitoring systems based on single-channel EEG analysis
Number of subjects: 0
Study: 11533340

Group type: EXPERIMENTAL
Intervention: Protein, energy, mineral, and micronutrient-enriched postdischarge formula (PDF; N = 113)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard term formula (TF; N = 116)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Breastfed until at least 6 weeks' postterm (Reference group; N = 65)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Protein, energy, mineral, and micronutrient-enriched postdischarge formula (PDF)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard term formula (TF)
Number of subjects: 284
Study: 9751013

Group type: EXPERIMENTAL
Intervention: Engerix B (1 ml, 20 micrograms)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hepavax (1 ml, 20 micrograms)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Gen Hevac B (combined S and PreS subunit vaccine, 1 ml, 20 micrograms)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard isolated S-antigen-containing vaccines (Engerix B or Hepavax)
Number of subjects: 76
Study: 7841897

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 20
Study: 3411179

Group type: COMPARATOR
Intervention: Human chorionic gonadotropin (hCG) 1500 IU intramuscularly on days +4, +7, +10, and +13
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Progesterone in oil 25 mg intramuscularly daily from day +4 to day +18
Number of subjects: 17
Study: 31654535

Group type: EXPERIMENTAL
Intervention: Interferon-free regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-based regimens
Number of subjects: 0
Study: 29040974

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cetuximab and Bevacizumab with Gemcitabine
Number of subjects: 127
Study: 26812509

Group type: EXPERIMENTAL
Intervention: Home based computerized cognitive training (CCT) 3x/week for 6 weeks, average of 23 minutes/session
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 25017114

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI), 15 °C to umbilicus
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Iced-slush ingestion (SLUSH), 7 g·kg(‐1) body weight
Number of subjects: 74

Group type: COMPARATOR
Intervention: Seated rest (CONT)
Number of subjects: 74
Study: 20851629

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 75
Study: 19654384

Group type: EXPERIMENTAL
Intervention: Screened group (n=3271) using the Woman Abuse Screening Tool (WAST) before the health care visit.
Number of subjects: 6743

Group type: COMPARATOR
Intervention: Nonscreened group (n=3472) using the WAST and other measures after their visit.
Number of subjects: 6743

Group type: EXPERIMENTAL
Intervention: Screened group (n=3271)
Number of subjects: 6743

Group type: COMPARATOR
Intervention: Nonscreened group (n=3472)
Number of subjects: 6743
Study: 17208671

Group type: EXPERIMENTAL
Intervention: Clens 100
Number of subjects: 22

Group type: COMPARATOR
Intervention: Blink‐N‐Clean
Number of subjects: 22

Group type: COMPARATOR
Intervention: No product
Number of subjects: 22
Study: 16342084

Group type: EXPERIMENTAL
Intervention: Arthritis Self‐Management Program (ASMP)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 355
Study: 11989042

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 45
Study: 9882992

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 33
Study: 8556970

Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1977949

Group type: EXPERIMENTAL
Intervention: Aerosolized beta 2‐agonists only
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined aerosolized beta 2‐agonists with intravenous AMP
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravenous AMP
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Aerosolized beta 2‐agonists
Number of subjects: 55
Study: 343788

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metamizole (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31370668

Group type: EXPERIMENTAL
Intervention: 3‐mL intra‐articular injection of atelocollagen (BioCollagen group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline (Placebo group)
Number of subjects: 200
Study: 31899823

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 6 months
Number of subjects: 37
Study: 31203242

Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 150

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 150
Study: 28207497

Group type: EXPERIMENTAL
Intervention: High hsCRP levels with OSA
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: Low hsCRP levels with OSA
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: High hsCRP levels without OSA
Number of subjects: 1835

Group type: COMPARATOR
Intervention: Low hsCRP levels without OSA
Number of subjects: 1835
Study: 25439774

Group type: EXPERIMENTAL
Intervention: Supervised training with a cardiothoracic surgeon or fellow (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unsupervised training (n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 45
Study: 23305083

Group type: EXPERIMENTAL
Intervention: Sequential therapy (20 mg rabeprazole and 1 g amoxicillin for the first week, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole for the second week)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (20 mg rabeprazole, 1 g amoxicillin, 500 mg clarithromycin, and 500 mg metronidazole for 2 weeks)
Number of subjects: 164
Study: 21067292

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment alone (control group)
Number of subjects: 60
Study: 19581544

Group type: EXPERIMENTAL
Intervention: Mothers with height shorter than 145 cm
Number of subjects: 3189

Group type: EXPERIMENTAL
Intervention: Mothers with mid‐upper arm circumference smaller than 21.5 cm
Number of subjects: 3189

Group type: EXPERIMENTAL
Intervention: Newborns with head circumference greater than 33.5 cm
Number of subjects: 3189

Group type: EXPERIMENTAL
Intervention: Infants born to mothers shorter than 145 cm weighing 3300 g
Number of subjects: 3189
Study: 16756218

Group type: EXPERIMENTAL
Intervention: Written material provided during counselling (n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Systematic counselling without written material (n = 26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recall of details about the cataract surgery procedure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Legal requirements for informed consent
Number of subjects: 50
Study: 15082697

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE)
Number of subjects: 10739
Study: 11735817

Group type: EXPERIMENTAL
Intervention: Ventilation tubes
Number of subjects: 187

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 187
Study: 9156377

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (500 mg every 12 hours)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study: 9113121

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tropisetron 10 mg
Number of subjects: 0
Study: 3534201

Group type: EXPERIMENTAL
Intervention: Thiopental treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 32
Study: 30442261

Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Seldinger technique
Number of subjects: 120
Study: 26682695

Group type: EXPERIMENTAL
Intervention: Supervised exercise group (60-min sessions three times a week for 16 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 23286558

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT), 11 to 13 sessions
Number of subjects: 3
Study: 22100355

Group type: EXPERIMENTAL
Intervention: Multidisciplinary cognitive behavioral treatment program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 61
Study: 15942709

Group type: EXPERIMENTAL
Intervention: 10 mg lafutidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: 20 mg rabeprazole
Number of subjects: 22
Study: 12197452

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Combined nefazodone/CBASP
Number of subjects: 681
Study: 10331896

Group type: EXPERIMENTAL
Intervention: 12x30 s at 175% PP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 12x2 min at 90% PP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 8x4 min at 85% PP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 12x60 s at 100% PP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4x8 min at 80% PP
Number of subjects: 20
Study: 7777129

Group type: EXPERIMENTAL
Intervention: Patients with epilepsy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 215

Group type: COMPARATOR
Intervention: Medical personnel observations
Number of subjects: 215
Study: 2148632

Group type: EXPERIMENTAL
Intervention: MPA treatment with mild exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment with mild exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: MPA treatment
Number of subjects: 12
Study: 6780292

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 15
Study: 31834099

Group type: EXPERIMENTAL
Intervention: LOW (150 mg·kg body mass tyrosine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MED (300 mg·kg body mass tyrosine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HIGH (400 mg·kg body mass tyrosine)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLA (0 mg tyrosine)
Number of subjects: 8
Study: 29486896

Group type: EXPERIMENTAL
Intervention: Treadmill-based stance-slip perturbation training protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo training protocol (Control)
Number of subjects: 0
Study: 28746178

Group type: EXPERIMENTAL
Intervention: High CMV viral load (>2.52 log copies/mL)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low CMV viral load (≤2.52 log copies/mL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low CMV-specific T-cell responses (<5 spots/2.0 × 10 PBMC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: High CMV-specific T-cell responses (≥5 spots/2.0 × 10 PBMC)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High CMV viral load and low CMV-specific T-cell responses
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low CMV viral load and low CMV-specific T-cell responses
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High CMV viral load and high CMV-specific T-cell responses
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low CMV viral load and high CMV-specific T-cell responses
Number of subjects: 76
Study: 24866870

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 77
Study: 23139359

Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: 20 mg/d atorvastatin
Number of subjects: 100
Study: 20980412

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (aimed at weight reduction, healthy diet, and increased physical activity) lasting for 4 years (range 1-6 years)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study: 17874029

Group type: EXPERIMENTAL
Intervention: 600 IU/day vitamin D3
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: 4200 IU/week vitamin D3
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: 18,000 IU/month vitamin D3
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 16154544

Group type: EXPERIMENTAL
Intervention: D-alanine (100 mg/kg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32